Status:
COMPLETED
Feasibility of Laryngeal Mask Airway Gastro on Patients Undergoing Endoscopic Retrograde Cholangiopancreatography for Pancreas and Bile Duct Disorders
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Bile Duct Disorder
Endocrine Pancreas Disorder
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This trial determines the feasibility of Laryngeal Mask Airway Gastro (Laryngeal Mask Airway) when used on patients who are undergoing endoscopic retrograde cholangiopancreatography for pancreas and b...
Detailed Description
PRIMARY OBJECTIVES: I. To determine the successful completion of endoscopic retrograde cholangiopancreatography (ERCP) with the Laryngeal Mask Airway (LMA) Gastro. SECONDARY OBJECTIVES: I. To deter...
Eligibility Criteria
Inclusion
- Adult patients undergoing elective ERCP with general anesthesia
Exclusion
- Patients with propofol allergy
- Patients at increased aspiration risk
- Patients with abnormal head/neck pathology preventing LMA Gastro placement
- Patients with surgical or radiation treatment to the head/neck making LMA Gastro placement difficult
- Esophagectomy patients
- Patients already intubated upon arrival to endoscopy suite
- Patients undergoing endoscopic ultrasound (EUS)
- Patients with body mass index (BMI) 35 kg/m\^2
- Non-English speaking patients
Key Trial Info
Start Date :
January 16 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 20 2020
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT03775681
Start Date
January 16 2019
End Date
April 20 2020
Last Update
April 27 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
M D Anderson Cancer Center
Houston, Texas, United States, 77030